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AntidepressantAn adult woman with Dravet syndrome (documented SCN1Amutation) experienced a marked reduction in sei-
zures when treated with the selective serotonin reuptake inhibitor (SSRI) ﬂuoxetine. The seizure reduction may
be partly due to reductions associated with aging in patients with Dravet syndrome, but it appears to be due, at
least in part, to ﬂuoxetine. A prior preliminary study reported that fenﬂuramine reduces seizures in patients with
Dravet syndrome. Fenﬂuraminemay produce this effect by increasing serotonin brain levels, and SSRIs have been
found to possess antiepileptic properties in animal models of epilepsy. Given the known cardiac risks of fenﬂur-
amine, randomized clinical trials with SSRIs should be considered in Dravet syndrome and other types of
epilepsy.
© 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Dravet syndrome is an epileptic encephalopathy, which was
ﬁrst described in 1978 [1,2]. It is a spectrum of conditions with vari-
ability in severity and manifestations but usually with catastrophic
consequences [3].1.1. Etiology
Mutations in the voltage-gated sodium-channel gene alpha subunit
(SCN1A) were discovered in an epileptic syndrome called genetic
epilepsy with febrile seizures plus (GEF+) including some patients
with severe myoclonic epilepsy of infancy (SMEI) in GEF+ families
[4–6]. Later, new SCN1A mutations were found in nonfamilial SMEI
[7]; thesemutationswere de novo andmore severe than those associated
with GEF+ [8]. Because some patients with the epileptic encephalopathy
do not exhibit myoclonus, the disorder is now known as Dravet
syndrome. Approximately 90% of patients with Dravet syndrome have
de novo mutations, about 75% of patients with Dravet syndrome have
mutations in the gene encoding SCN1A, and over 300 SCN1A mutationse serotonin reuptake inhibitor;
myoclonic epilepsy of infancy;
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Dravet syndrome include PCDH19, GABRG2, and SCN1B [8].
Animal models exhibit the characteristic temperature/age depen-
dent seizures seen in humans, and there is a 50% reduction in sodium
current in heterozygous SCN1Amutations [10]. Since the SCN1A protein
is expressed predominately in GABAergic interneurons as opposed to
excitatory pyramidal neurons, Dravet syndrome is considered a genetic
dysfunction of inhibitory interneurons [8,11].
1.2. Clinical manifestations
Onset is typically in the ﬁrst year of life in a previously healthy infant
who experiences a seizure associated with fever, vaccination, or illness
[8]. Initial seizures are generalized or hemiclonic, and the ﬁrst seizure
may be status epilepticus. Over the next few years, other seizure types
usually develop, which may include atypical absence, focal (with im-
paired consciousness),myoclonic, atonic, and tonic seizures and convul-
sive or nonconvulsive status. Seizuresmay be triggered by fever, fatigue,
photosensitivity, or excitement [2]. By the age of 2 years, developmen-
tal delay is usually apparent. Deterioration occurs from ages 1 to 4 years
with the occurrence of psychomotor, behavioral, and gait abnormalities
[2]. After age 5, convulsive seizures usually decrease and may occur
mainly in sleep [2]. Cognitive and behavioral problems stabilize and
may improve to a degree, but at least half of patients remain severely
impaired. Magnetic resonance imaging shows only diffuse atrophy,
and EEGmay have diffuse slowingwith generalized spike and polyspike
and wave discharges and/or multifocal epileptiform discharges [8]. The
seizures are typically medically resistant. Carbamazepine, lamotrigine,-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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stiripentol, and topiramate are the most effective antiepileptic drugs.
However, seizures persist into adulthood [8]. Mortality is about 15% by
adulthood in patients with Dravet syndrome [8].
2. Case report
The case report described here was carried out in accordance with
the Code of Ethics of the World Medical Association (Declaration of
Helsinki). DL is a 27-year-old woman with Dravet syndrome. She has
a conﬁrmed SCN1Amutation with deletion of 1 bp of C nucleotide posi-
tion 1650, codon 550. Her ﬁrst seizure occurred at age 4 months after a
diphtheria–pertussis–tetanus vaccination without fever; it consisted of
some left-arm jerks. She had her ﬁrst convulsion at age 6 months and
her ﬁrst episode of status epilepticus at age 3 years after which her
development was noted to be distinctly abnormal. Over the years, DL
suffered frommultiple seizure types including generalized tonic–clonic,
focal (with impaired consciousness), andmyoclonic seizures and atonic
drop attacks. Seizures were increased with fever and later in a catame-
nial pattern. Her seizures failed to improve with multiple antiepileptic
drugs including carbamazepine, clobazam, clonazepam, clorazepate,
felbamate, lamotrigine, levetiracetam, lorazepam, phenobarbital,
phenytoin, primidone, retigabine, stiripentol, tiagabine, topiramate,
valproate, and zonisamide. A strict ketogenic diet and vagal nerve
stimulation also failed to improve her seizures.
Magnetic resonance imaging showed only diffuse atrophy. Electro-
encephalograms and video-EEGs revealed multifocal spikes and
polyspikes interictally, and recorded generalized tonic–clonic seizures
had ictal onsets with diffuse decrement. Her genetic diagnosis was
made at age 21 years.
In late July 2009, DL was started on ﬂuoxetine 20 mg daily in an at-
tempt to reduce stereotypic behaviors characterized as vigorous back-
and-forth head shaking, which was sometimes associated with facial
grimace and raising of her legs into a ﬂexed position. These behaviors
occurredmultiple times per day but did not occur out of sleep. The fam-
ily thought that they could sometimes be interrupted with distraction.
At the time, DL's medications included felbamate (2400 mg/day),
levetiracetam (1000 mg/day; higher dosages were ineffective and
caused behavioral problems), diazepam PR PRN, lorazepam PO PRN,
fexofenadine PRN, medroxyprogesterone, polyethylene glycol, melato-
nin, and multivitamins. Her last prior medication change had been ta-
pering and then stopping of stiripentol in May 2009, which did not
cause any worsening of her seizures on withdrawal.
Fluoxetine therapy was effective in markedly reducing the stereo-
typic behaviors, but, surprisingly, it was also associated with a marked
reduction in seizures. In the months preceding ﬂuoxetine in that year,
DL had an average of 8–10 seizures permonth. In the remainingmonths
of that year after initiation of ﬂuoxetine, DL's seizure frequency dropped
to 3–4 per month, and the seizures were less severe. This reduction in
seizures has been maintained, and the seizures even improved over
subsequent years without any other changes in antiepileptic drugs.
Her seizures were predominantly generalized tonic–clonic seizures
in recent years. Now, they are rare, brief, and usually nocturnal. Her
behavior and cognitive function have also had modest improvements
(see Table 1 for annual seizure rates).Table 1
Total annual seizures for DL. Note that ﬂuoxetine was initiated in the later half of 2009.
Year Total # of seizures
2007 116
2008 95
2009 93
2010 37
2011 16
2012 12
2013 43. Discussion
The observed reduction in seizure could be due to the natural reduc-
tion in seizures in patientswithDravet syndrome that occurswith aging
[2]. However, ﬂuoxetine was begun at age 24 years, and the seizure re-
duction typically occurs before that age. Fluoxetine is a selective seroto-
nin reuptake inhibitor (SSRI). Recently, a preliminary study showed
remarkable efﬁcacy for fenﬂuramine in reducing seizures in patients
with Dravet syndrome [12]. Fenﬂuramine increases serotonin levels
via inhibition of serotonin uptake and disruption of serotonin of vesicu-
lar storage [12].
Several investigations suggest that serotonin possesses antiepileptic
properties [13]. For example, SSRIs increase extracellular 5-HT, which
inhibits focal and generalized seizures in several animal models of
generalized epilepsy and focal epilepsy [14–16]. Activation of 5HT1A
receptors can result in membrane hyperpolarizing associated with
increased potassium conductance [17,18], and stimulation of 5HT1A re-
ceptors in the thalamus can increase GABA release, reducing excitation
in an animal model [19]. Further, 5HT2C agonists prevent seizures,
and 5HT2C antagonists lower seizure threshold in both focal and
generalized models of epilepsy [20]. In humans, three open trials
with SSRIs have also suggested possible antiepileptic effects
[21–23]. Speciﬁcally in regard to ﬂuoxetine, an open trial of 17 patients
with focal epilepsy followed over amean of 14 months reported seizure
freedom in 6 patients and decreased seizure frequency by 30% in the
other 11 patients [23]. Thus, the observed response to ﬂuoxetine in DL
may be due to its serotonin effects.
4. Conclusions
This case report suggests that the SSRI ﬂuoxetine may have efﬁcacy
in reducing seizures in Dravet syndrome. The ﬁnding is consistent
with the preliminary ﬁndings of antiseizure efﬁcacy for fenﬂuramine,
another agent with serotonergic effects. In addition, several investiga-
tions in animals suggest that serotonin agents possess antiepileptic
properties. Given the potential adverse cardiac effects of fenﬂuramine,
randomized clinical trials of other serotoninergic agents like ﬂuoxetine
should be considered in patients with Dravet syndrome and other
types of epilepsy.
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